HC Wainwright Reiterates Buy Rating on uniQure N.V.
Analyst Patrick R. Trucchio keeps a buy rating for uniQure with an $80 price target, a 72.32% upside from the current price.
Key Points
- On June 29, 2026, HC Wainwright reiterated its buy rating for uniQure N.V. (QURE) with a price target of $80.
- HC Wainwright's $80 price target implies 72.32% upside from uniQure N.V.'s ($QURE) current $46.42 share price.
- Shares of NasdaqGS:QURE traded near $47.51 on Monday, with a market cap of approximately $3.27 billion.
- Other analysts like Mizuho and Barclays also maintain buy ratings, with targets at $68 and $65 respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HC Wainwright has reiterated its buy rating for uniQure N.V. (NasdaqGS:QURE), maintaining a price target of $80. This update came on June 29, 2026, with analyst Patrick R. Trucchio continuing to support the stock.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
uniQure N.V. Stock Down 4.7%
Shares of uniQure N.V. traded around $47.51 on Monday. The company, which operates in the biotechnology sector, has a market capitalization of about $3.27 billion. While it is not currently profitable, with a forward P/E ratio of -16.11, the stock has shown volatility with a 52-week range between $8.73 and $71.5. uniQure's liquidity is strong, with a current ratio of 10.4 and a quick ratio of 10.0, though it carries a high debt-to-equity ratio of 365.4.
$QURE price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
uniQure reported revenue of approximately $18.1 million, seeing a growth of 1.3% from the previous period. However, the company has a negative return on equity of -228.2%, and its net margin stands at zero. Investors are looking ahead to the next earnings report, expected on July 29, 2026.
Insider Buying and Selling at uniQure N.V.
Recently, there have been insider transactions by CEO Matthew Kapusta. On June 25, 2026, Kapusta bought 28,716 shares at $31.71 per share and sold the same amount under a planned sale at $50.02. On June 24, he bought 4,128 shares at $31.71 and sold 6,696 shares at $50.00, also under a planned sale.
Analysts Set New Price Targets
HC Wainwright's recent reiteration of a buy rating for uniQure comes alongside other analysts' views. On June 25, 2026, Mizuho maintained its buy rating with a $68 target. Earlier in June, Barclays upgraded the stock to a buy with a $65 target, while Goldman Sachs held a neutral stance with a $46 target. The consensus among analysts is strong, with a mean target price of $61.68 and a "strong buy" recommendation.
About uniQure N.V.
uniQure N.V. is a biotechnology company based in Amsterdam, Netherlands, focused on developing gene therapies for rare diseases. Its flagship product, HEMGENIX, helps patients with hemophilia B. The company is also working on treatments for Huntington's disease and other conditions. Founded in 1998, uniQure is led by CEO Matthew Craig Kapusta and employs around 221 people.
Bottom Line
uniQure N.V. continues to attract attention from analysts, with HC Wainwright reaffirming its buy rating and setting a high price target. Although the company is not yet profitable, its innovative treatments and strong liquidity position it as a noteworthy player in the biotechnology sector. Investors should remember that analyst ratings are based on past data and market conditions can change.
Get uniQure N.V. alerts
New 13F filings, insider trades, and analyst moves on $QURE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.